"Interleukin-2" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A soluble substance elaborated by antigen- or mitogen-stimulated T-LYMPHOCYTES which induces DNA synthesis in naive lymphocytes.
| Descriptor ID |
D007376
|
| MeSH Number(s) |
D12.644.276.374.465.021 D12.644.276.374.480.372 D12.776.467.374.465.021 D12.776.467.374.480.372 D23.529.374.465.155 D23.529.374.480.372
|
| Concept/Terms |
Interleukin-2- Interleukin-2
- Interleukin 2
- IL-2
- IL2
- TCGF
- Interleukine 2
- Lymphocyte Mitogenic Factor
- Mitogenic Factor, Lymphocyte
- T-Cell Growth Factor
- T Cell Growth Factor
- T-Cell Stimulating Factor
- T Cell Stimulating Factor
- Thymocyte Stimulating Factor
- Interleukin II
Ro-23-6019- Ro-23-6019
- Ro 23 6019
- Ro236019
- Ro-236019
- Ro 236019
|
Below are MeSH descriptors whose meaning is more general than "Interleukin-2".
Below are MeSH descriptors whose meaning is more specific than "Interleukin-2".
This graph shows the total number of publications written about "Interleukin-2" by people in this website by year, and whether "Interleukin-2" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 3 | 3 | 6 |
| 1997 | 3 | 0 | 3 |
| 1998 | 2 | 8 | 10 |
| 1999 | 3 | 2 | 5 |
| 2000 | 2 | 3 | 5 |
| 2001 | 3 | 1 | 4 |
| 2002 | 1 | 5 | 6 |
| 2003 | 0 | 2 | 2 |
| 2004 | 1 | 4 | 5 |
| 2005 | 5 | 5 | 10 |
| 2006 | 0 | 4 | 4 |
| 2007 | 3 | 2 | 5 |
| 2008 | 3 | 6 | 9 |
| 2009 | 3 | 4 | 7 |
| 2010 | 1 | 5 | 6 |
| 2011 | 3 | 1 | 4 |
| 2012 | 1 | 4 | 5 |
| 2013 | 0 | 2 | 2 |
| 2014 | 2 | 3 | 5 |
| 2015 | 0 | 2 | 2 |
| 2016 | 1 | 1 | 2 |
| 2017 | 2 | 4 | 6 |
| 2018 | 1 | 1 | 2 |
| 2019 | 1 | 2 | 3 |
| 2020 | 3 | 1 | 4 |
| 2022 | 3 | 4 | 7 |
| 2023 | 0 | 3 | 3 |
| 2024 | 1 | 0 | 1 |
| 2025 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Interleukin-2" by people in Profiles.
-
IL-2-independent expansion, persistence, and antitumor activity in TIL expressing regulatable membrane-bound IL-15. Mol Ther. 2025 Aug 06; 33(8):3605-3623.
-
IL-2/anti-IL-2 antibody complexes augment immune responses to therapeutic cancer vaccines. Proc Natl Acad Sci U S A. 2024 11 26; 121(48):e2322356121.
-
Bempegaldesleukin Plus Nivolumab in Untreated Advanced Melanoma: The Open-Label, Phase III PIVOT IO 001 Trial Results. J Clin Oncol. 2023 10 20; 41(30):4756-4767.
-
Conditional deletion of CD25 in the corneal epithelium reveals sex differences in barrier disruption. Ocul Surf. 2023 10; 30:57-72.
-
Prevention of acute GVHD using an orthogonal IL-2/IL-2R? system to selectively expand regulatory T?cells in?vivo. Blood. 2023 03 16; 141(11):1337-1352.
-
Antibody and T cell responses against wild-type and Omicron SARS-CoV-2 after third-dose BNT162b2 in adolescents. Signal Transduct Target Ther. 2022 12 14; 7(1):397.
-
Activation of Adaptive and Innate Immune Cells via Localized IL2 Cytokine Factories Eradicates Mesothelioma Tumors. Clin Cancer Res. 2022 12 01; 28(23):5121-5135.
-
PD-1 combination therapy with IL-2 modifies CD8+ T cell exhaustion program. Nature. 2022 10; 610(7930):173-181.
-
Responses of regulatory and effector T-cells to low-dose interleukin-2 differ depending on the immune environment after allogeneic stem cell transplantation. Front Immunol. 2022; 13:891925.
-
The microRNA-183/96/182 cluster inhibits lung cancer progression and metastasis by inducing an interleukin-2-mediated antitumor CD8+ cytotoxic T-cell response. Genes Dev. 2022 05 01; 36(9-10):582-600.